Sector News

Sanofi’s Plump tapped to head Takeda R&D from Cambridge base

December 18, 2014
Life sciences
The new president at Takeda has raided Sanofi for its new head of global R&D. And they’re putting their new top scientist in Cambridge, MA, which is becoming the world headquarters of drug research for much of the pharma industry.
 
Andrew “Andy” Plump has been lured to the top job at Takeda research after completing a stint as SVP of research and translational medicine at Sanofi, where he worked in Paris. Plump, though, has deep roots in Cambridge, where he got his B.S. at MIT before getting his M.D. at UC San Francisco and a PhD at Rockefeller University. After his education he worked as a VP of cardiovascular at Merck.
 
A Takeda spokesperson told Bloomberg that Plump will be based in Cambridge, MA, where the company has been reorganizing its oncology work. Takeda bought out Millennium, but recently dropped the iconic name.
 
The globalization of Takeda’s leadership began in earnest with the recent appointment of Christophe Weber as the new president, now in line to become the first non-Japanese CEO in 230 years – a fact that has ruffled more than a few feathers in Japan, where “foreigners” have not been welcome by former execs and shareholders. Weber was brought in to revamp Takeda as the company’s blockbuster Actos revenue has begun to disappear in the face of generic competition. U.S. president Doug Coles was recently ousted in the management shakeup that followed.  
 
Sanofi, meanwhile, is losing an American exec in the wake of Christopher Viehbacher’s stormy showdown with a French chairman of the board. 
 
Global pharma organizations like Pfizer, Novartis and others have been putting a growing emphasis on work around the Boston area, where biotech has been booming for years in neighborhoods close to MIT and Harvard. GlaxoSmithKline recently opened a new office to scout for deals in the area, following a similar move by J&J.
 
Takeda has had some success in the recent past, most notably the approval of vedolizumab for inflammatory bowel disease. But it’s also had late-stage failures for TAK-875, or fasiglifam, as well as their top cancer contender at Millennium. Those setbacks helped trigger a plan to carve $1 billion out of its budget and lay off thousands.
 
By John Carroll
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach